Last Updated : April 1, 2024
Details
Generic Name:
remdesivir
Project Status:
Active
Therapeutic Area:
COVID-19 in hospitalized patients
Manufacturer:
Gilead Sciences Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Veklury
Project Line:
Reimbursement Review
Project Number:
SR0833-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Hospitalized patients 12 years of age (weighing at least 40 kg) with pneumonia requiring supplemental oxygen.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Hospitalized patients ≥12 years of age (weighing at least 40 kg) with pneumonia requiring supplemental oxygen.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 08, 2024 |
|---|---|
| Call for patient/clinician input closed | March 04, 2024 |
| Clarification: - No patient input submission received | |
| Submission received | March 01, 2024 |
| Submission accepted | March 18, 2024 |
| Review initiated | March 19, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | May 13, 2024 |
| Deadline for sponsors comments | May 23, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | June 14, 2024 |
| Expert committee meeting (initial) | June 26, 2024 |
| Draft recommendation issued to sponsor | July 09, 2024 To July 11, 2024 |
| Draft recommendation posted for stakeholder feedback | July 18, 2024 |
| End of feedback period | August 01, 2024 |
Last Updated : April 1, 2024